证券代码： 600566 证券简称： 济川药业 公告编号： 2025-050 湖北济川药业股份有限公司 关于收到药品注册申请受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，湖北济川药业股份有限公司（以下简称"公司"）全资子公司济川药 业集团有限公司（以下简称"济川有限"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的"小儿便通颗粒"申报上市许可的《受理通知书》，现 将情况公告如下： 二、 药品相关情况 小儿便通颗粒来源于陈永辉医生（现首都医科大学附属首都儿童医学中心， 中医科主任医师）行医多年的验方，其处方已申请专利；具有健脾和胃、行气导 滞的功效，用于小儿便秘，中医辨证属食积证者。根据国家药监局网站信息显示， 中国境内（不包括港澳台地区）暂无与其处方一致的药品上市或注册申报信息。 2025 年 7 月 8 日 三、 同类产品市场情况 目前，市场上可用于小儿便秘的同类产品主要用于其他疾病伴发的便秘症状， 临床尚无治疗小儿便秘的儿童专用中药创新药。该产品有望成为指导原则《小儿 便秘中药新药临床研 ...

Group 1 - The company has received a notice of acceptance for the registration application of "Children's Constipation Granules" from the National Medical Products Administration, marking the entry into the review stage for domestic production registration [1][2] - The product is derived from a patented formula by Dr. Chen Yonghui, aimed at treating pediatric constipation with specific efficacy in strengthening the spleen and stomach, and promoting digestion [1][2] - Currently, there are no similar registered products in China specifically for treating pediatric constipation, positioning this product as a potential first in its category following the release of new clinical guidelines in 2024 [2] Group 2 - The project has accumulated an investment of approximately 51.42 million yuan [2] - The acceptance of the registration application does not have a significant immediate impact on the company's current performance, but the sales post-launch may be subject to various market factors [2]

济川药业（600566）公告，全资子公司济川有限收到国家药监局签发的"小儿便通颗粒"申报上市许可的 《受理通知书》。该药品为中药1.1类，用于小儿便秘，处方已申请专利。目前，中国境内暂无与其处 方一致的药品上市或注册申报信息。该项目累计投入约5141.92万元。该产品有望成为首个用于小儿便 秘的中药1.1类儿童专用药。药品审评受理不会对本公司现阶段业绩产生重大影响。 ...

Core Viewpoint - The report outlines the offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd. by Cao Fei, which triggers a mandatory tender offer due to the increase in shareholding above 30% [19][24]. Group 1: Company Overview - Hubei Jichuan Pharmaceutical Co., Ltd. focuses on the research, production, and sales of pharmaceuticals, particularly in pediatrics, respiratory, digestive, and gynecological fields [7][8]. - The company has developed a core product matrix that includes pediatric medications and treatments for upper respiratory infections [8]. Group 2: Financial Data - The company's recent financial performance shows total revenue of 965,453.72 million yuan in 2023, with a net profit of 282,706.30 million yuan [9]. - The financial indicators for the first quarter of 2025 indicate a net profit of 44,129.27 million yuan, with a gross margin of 77.25% [10][11]. Group 3: Shareholding Structure - As of the report date, the total issued shares of the company are 921,704,160, with 99.35% being freely tradable [11]. - The report indicates that the acquirer, Cao Fei, does not currently hold shares in the company, while his associated parties hold significant stakes [18]. Group 4: Acquisition Details - The offer price for the tender is set at 24.85 yuan per share, which is based on the average price over the last 30 trading days prior to the announcement [20][21]. - The acquisition is structured to comply with legal requirements, ensuring that the company remains publicly listed post-acquisition [24]. Group 5: Independent Financial Advisor - Guojin Securities has been appointed as the independent financial advisor for the acquisition, confirming that the offer complies with relevant laws and regulations [24][23]. - The independent advisor's report supports the board's recommendation for shareholders to consider the offer based on the company's future prospects and market conditions [23][24].

湖北济川药业股份有限公司董事会 关于 曹飞 要约收购事宜 致全体股东的报告书 | 上市公司名称： | 湖北济川药业股份有限公司 | | --- | --- | | 股票上市地点： | 上海证券交易所 | | 股票简称： | 济川药业 | | 股票代码： | 600566.SH | 董事会报告签署日期：二零二五年七月 有关各方及联系方式 上市公司（被收购人）名称：湖北济川药业股份有限公司 联系地址：江苏省泰兴市大庆西路宝塔湾 联系人：曹伟 电话：0523-89719161 收购人名称：曹飞 收购人住所：上海市黄浦区**** 独立财务顾问名称：国金证券股份有限公司 独立财务顾问办公地址：上海市浦东新区芳甸路1088号23层 联系人：季文浩、吴卓 联系电话：021-68826021 1 董事会声明 一、本公司全体董事确信本报告书不存在任何虚假记载、误导性陈述或重大 遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 二、本公司全体董事已履行诚信义务，向股东所提出的建议是基于公司和全 体股东的整体利益客观审慎做出的。 三、本公司关联董事曹龙祥、曹飞、黄曲荣已回避对本报告书的审议表决， 本公司其他董事没有任何与本次 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-049 湖北济川药业股份有限公司 1.被收购公司名称：湖北济川药业股份有限公司 2.被收购公司股票名称：济川药业 3.被收购公司股票代码：600566 4.收购股份种类：无限售条件的流通股 5.预定收购的股份数量：350,841,357 股 6.预定收购股份占被收购公司总股本比例：38.06% 7.支付方式：现金 9.要约有效期：自 2025 年 6 月 18 日至 2025 年 7 月 17 日 关于曹飞先生要约收购公司股份的第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生自 2025 年 6 月 18 日起要约收购公司股份 350,841,357 股。本次 要约收购的具体情况如下： 一、 本次要约收购的基本情况 8.要约价格：24.85 元/股 （鉴于公司 2024 年年度利润分配方案已实施完 毕，本次要约收购的要约收购价格 ...

国金证券股份有限公司 关于 曹飞 要约收购 湖北济川药业股份有限公司 之 独立财务顾问报告 二〇二五年七月 独立财务顾问声明和承诺 本部分所述的词语或简称与本独立财务顾问报告书"释义"部分所定义的词 语或简称具有相同的涵义。 国金证券股份有限公司接受湖北济川药业股份有限公司的委托，担任本次要 约收购的独立财务顾问。本报告所依据的有关资料由上市公司、收购人及其一致 行动人等相关机构及人员提供，并由提供方承诺对其所提供的一切书面材料、文 件或口头证言的真实性、准确性和完整性负责，并不存在虚假记载、误导性陈述 或重大遗漏。 除上市公司、收购人及其一致行动人等相关机构及人员所提供的相关信息外， 本报告所依据的其他信息均来自公开渠道，包括但不限于上市公司最近三年的定 期报告、资本市场公开数据等。 本报告仅就本次收购人要约收购上市公司事宜发表意见，包括要约收购条件 是否公平合理、收购可能对上市公司产生的影响等。对投资者根据本报告做出的 任何投资决策可能产生的后果，本独立财务顾问不承担任何责任。 截至本独立财务顾问报告出具日，本独立财务顾问与本次要约收购的所有当 事各方没有任何关联关系，本独立财务顾问就本次要约收购发表的有 ...

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

证券代码：600566 证券简称：济川药业 公告编号：2025-048 公司于 2024 年 7 月 22 日召开了第十届董事会第十次会议、第十届监事会第 十次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同 意公司使用自有资金通过集中竞价交易方式回购部分公司股份，用于实施员工持 股计划或股权激励。本次回购的资金总额不低于人民币 2,500 万元（含）且不超 过人民币 5,000 万元（含），回购价格不超过人民币 48 元/股（含）。回购股份实施 期限为自公司董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详见 公司于 2024 年 7 月 23 日在上海证券交易所网站（http://www.sse.com.cn）披露 的《湖北济川药业股份有限公司关于以集中竞价交易方式回购公司股份方案的公 告暨回购报告书》（公告编号：2024-037）。 湖北济川药业股份有限公司关于 以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | ...

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]